Studies biomarkers in motor neuron disease and frontotemporal dementia
Looks for markers in adults with motor neuron disease or frontal dementia.
Plain-language title generated from the registry record
Registry title: Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-80 with motor neuron disease or frontotemporal dementia spectrum disease, and for people of the same age and sex without such disease as a control group.
- Age
- 18-80 years
- Sex
- All sexes
- Disease stage
- Motor neuron disease / frontotemporal dementia spectrum disease (ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD), diagnosed by an experienced neurologist using set diagnostic criteria and clinical guidelines.
Main reasons for not taking part
- Patients whose diagnosis changes to a different one during follow-up cannot join.
- Control people with any neurological disease, such as dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis or neuromyelitis, cannot join.
- People who do not sign informed consent cannot join.
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04961450, who can take part
Where in China
- Dongsheng FanBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT04961450
- Record updated
- 14 July 2021
- Original description
1. To investigate the biomarkers of MND/FTD spectrum disease 2. To explore the possible pathogenesis of MND/FTDRead full original descriptionShow less
A Study on the Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China
1. To investigate the biomarkers of MND/FTD spectrum disease 2. To explore the possible pathogenesis of MND/FTD
Inclusion: Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020; Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines; Informed consent signed Exclusion Criteria; Patients who receive alternative diagnoses during the follow-up; Patients who refuse to sign informed consent; Control group:; Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.
Exclusion: Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on; Individuals who refuse to sign informed consent.
Patients:.